Mechanisms of resistance to chimeric antigen receptor t cell therapy
GA Johnson, FL Locke - Hematology/Oncology Clinics, 2023 - hemonc.theclinics.com
Background Chimeric antigen receptor (CAR) T-cell therapy has proved effective for putting
both indolent and aggressive malignancies into remissions that endure longer than former …
both indolent and aggressive malignancies into remissions that endure longer than former …
CD19-directed CAR T cells as first salvage therapy for large B-cell lymphoma: towards a rational approach
P Dreger, P Corradini, JG Gribben, B Glass… - The Lancet …, 2023 - thelancet.com
The approval of CD19-directed chimeric antigen receptor (CAR) T-cell therapies for the
second-line treatment of high-risk large B-cell lymphoma (LBCL) has greatly affected …
second-line treatment of high-risk large B-cell lymphoma (LBCL) has greatly affected …
Safety and efficacy of axicabtagene ciloleucel versus standard of care in patients 65 years of age or older with relapsed/refractory large B-cell lymphoma
Purpose: Older patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) may be
considered ineligible for curative-intent therapy including high-dose chemotherapy with …
considered ineligible for curative-intent therapy including high-dose chemotherapy with …
Product attributes of CAR T-cell therapy differentially associate with efficacy and toxicity in second-line large B-cell lymphoma (ZUMA-7)
Abstract Treatment resistance and toxicities remain a risk following chimeric antigen
receptor (CAR) T-cell therapy. Herein, we report pharmacokinetics, pharmacodynamics, and …
receptor (CAR) T-cell therapy. Herein, we report pharmacokinetics, pharmacodynamics, and …
Axicabtagene ciloleucel versus standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume
FL Locke, OO Oluwole, J Kuruvilla, C Thieblemont… - Blood, 2024 - Elsevier
Metabolic tumor volume (MTV) assessed using 2-deoxy-2-[18 F] fluoro-D-glucose positron
emission tomography, a measure of tumor burden, is a promising prognostic indicator in …
emission tomography, a measure of tumor burden, is a promising prognostic indicator in …
Challenges identifying DLBCL patients with poor outcomes to upfront chemoimmunotherapy and its impact on frontline clinical trials
Diffuse large B cell lymphoma (DLBCL) has a variable course of disease among patients as
it consists of subgroups that are clinically, biologically and molecularly heterogeneous. In …
it consists of subgroups that are clinically, biologically and molecularly heterogeneous. In …
I (Don't) Want My MTV: Higher Metabolic Tumor Volume Predicts Poor Outcomes in Second-Line Large B-Cell Lymphoma, Although Axi-Cel Still Outperforms …
G Shouse, AF Herrera - The Hematologist, 2024 - ashpublications.org
I (Don’t) Want My MTV: Higher Metabolic Tumor Volume Predicts Poor Outcomes in Second-Line
Large B-Cell Lymphoma, Although Axi-Cel Still Outperforms Standard of Care | The …
Large B-Cell Lymphoma, Although Axi-Cel Still Outperforms Standard of Care | The …